Core Viewpoint - The company is strategically enhancing its investment in the AI medical field through mergers and acquisitions, as well as a combination of B2B and B2C approaches, aiming to develop a robust AI ecosystem that provides valuable medical tools and products [1] Group 1: AI Medical Strategy - Since 2018, the company has proactively positioned itself in the AI medical sector by implementing a "mergers + hospital + C-end" strategy to build a comprehensive AI medical ecosystem [2] - The company has successfully integrated three companies—Saiweisen Medical Technology, Shengqiang Technology, and Yizhun Intelligent—into its ecosystem, each excelling in imaging, pathology, and laboratory diagnostics [2] - Saiweisen Medical Technology received the first domestic Class III medical device registration for cervical cancer cell digital pathology image-assisted diagnostic software in February 2025, highlighting its leading position in the pathology AI field [2] Group 2: Business Growth and Future Outlook - The company's overseas business is showing strong growth, particularly in the emergency scene and the U.S. market for respiratory triad testing products, which is expected to significantly boost overseas revenue by 2026 [2] - The company is committed to innovation as a core driver and plans to continue increasing investments in the AI medical field, focusing on a multi-modal diagnostic architecture that combines imaging, pathology, and laboratory diagnostics [3] - Despite a strategic adjustment in 2025 that temporarily impacted profit margins, the company anticipates a strong recovery in domestic business growth in 2026, supported by a low base from 2025 and positive expectations for overseas business growth [3]